SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    A. Alonso Cánovas, R. Luquin Piudo, P. García Ruiz-Espiga, J.A. Burguera, V. Campos Arillo, A. Castro, G. Linazasoro, J. López del Val, L. Vela, J.C. Martínez Castrillo, Agonistas dopaminérgicos en la enfermedad de Parkinson, Neurología, 2014, 29, 4, 230

    CrossRef

  2. 2
    Hiroshi Kataoka, Satoshi Ueno, Auditory Musical Hallucinations Associated With Extended-Release Pramipexole in an Elderly Patient With Parkinsonʼs Disease, Medicine, 2014, 93, 27, e251

    CrossRef

  3. 3
    A. Alonso Cánovas, R. Luquin Piudo, P. García Ruiz-Espiga, J.A. Burguera, V. Campos Arillo, A. Castro, G. Linazasoro, J. López Del Val, L. Vela, J.C. Martínez Castrillo, Dopaminergic agonists in Parkinson's disease, Neurología (English Edition), 2014, 29, 4, 230

    CrossRef

  4. 4
    Matthias Löhle, Carl-Johan Ramberg, Heinz Reichmann, Anthony H. V. Schapira, Early Versus Delayed Initiation of Pharmacotherapy in Parkinson’s Disease, Drugs, 2014, 74, 6, 645

    CrossRef

  5. 5
    Chang-Qing Zhou, Jing-He Lou, Yu-Ping Zhang, Ling Zhong, Ya-Lan Chen, Feng-Jiao Lu, Guo-Guang Peng, Long-Acting Versus Standard Non-Ergot Dopamine Agonists in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials, CNS Neuroscience & Therapeutics, 2014, 20, 4
  6. 6
    R. A. Hauser, A. H. V. Schapira, P. Barone, Y. Mizuno, O. Rascol, M. Busse, C. Debieuvre, M. Fraessdorf, W. Poewe, Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease, European Journal of Neurology, 2014, 21, 5
  7. 7
    James E. Frampton, Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson’s Disease, Drugs, 2014, 74, 18, 2175

    CrossRef

  8. 8
    Qing Lv, Baorong Zhang, Application of the concept of continuous dopaminergic stimulation for the management of Parkinson’s disease, Neuroscience Bulletin, 2013, 29, 5, 661

    CrossRef

  9. 9
    Scott Kaplan, Daniel Tarsy, Initial Treatment of Parkinson’s Disease: An Update, Current Treatment Options in Neurology, 2013, 15, 4, 377

    CrossRef

  10. You have free access to this content10
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  11. 11
    John C. P. Piedad, Andrea E. Cavanna, Dyskinesias and Treatment with Pramipexole in Patients with Parkinson's Disease, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  12. 12
    Fabrizio Stocchi, Continuous dopaminergic stimulation and novel formulations of dopamine agonists, Journal of Neurology, 2011, 258, S2, 316

    CrossRef

  13. 13
    O. Rascol, Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release, European Journal of Neurology, 2011, 18,
  14. 14
    Eva-Maria Hametner, Klaus Seppi, Werner Poewe, Pramipexole extended release in Parkinson’s disease, Expert Review of Neurotherapeutics, 2011, 11, 9, 1229

    CrossRef

  15. 15
    Santiago Perez-Lloret, María Verónica Rey, Luca Ratti, Olivier Rascol, Pramipexole for the treatment of early Parkinson’s disease, Expert Review of Neurotherapeutics, 2011, 11, 7, 925

    CrossRef